Join us

Publications

View here

Latest Publications

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) – a multinational team initiative.

Gynecologic Oncology, May 2026

Transforming Endometrial Cancer Diagnosis: The Case for Molecular Triage in Abnormal Uterine and Postmenopausal Bleeding

International Journal of Gynecological Cancer, May 2026

Morbidity, Recurrence and Survival Following Pelvic Exenteration for Gynaecological Malignancies: A Retrospective, Single-Centre Study

Journal of Clinical Medicine, May 2026

Quality of Life Outcomes Following Pelvic Exenteration for Gynaecological Malignancies: A Systematic Review

Anticancer Research, June 2026

Key Publications

Cost -Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer

Read more

A Cost-Effectiveness Analysis for Multigene Testing for All Patients With Breast Cancer

Read more

Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women

Read more

Specifying the ovarian cancer risk threshold of ‘premenopausal risk-reducing salpingo-oophorectomy’ for ovarian cancer prevention: a cost-effectiveness analysis

Read more

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

Read more

Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention

Read more

Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial

Read more

Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study

Read more

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer

Read more

Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes

Read more

All Publications

To view a full list of our publications please click in the search bar below. This gives you the option to search for a specific author or topic, or scroll through the references chronologically.

first row
1Seksaf N.A, Roberts, H.L., Lewis, M.E., Smits, A., Oxley, S.G., Lymperopoulos, N., Jeyarajah, A., Manchanda, R., Phadnis., S., Sideris, M. (2026). International Institute of Anticancer Research.

doi: https://doi.org/10.21873/anticanres.18172


Keywords: Pelvic exenteration; quality of life; gynaecological malignancy; review
2Zalawadia, S., Lekka, S., Al-Jumaili, Z., Brockbank, E., Manchanda, R., Jeyarajah, A., Phadnis, S. and Sideris, M. 2026. Morbidity, Recurrence and Survival Following Pelvic Exenteration for Gynaecological Malignancies: A Retrospective, Single-Centre Study. Journal of Clinical Medicine.

doi: 10.3390/jcm15103957


Keywords:
pelvic exenteration; gynaecological malignancies; morbidity; recurrence patterns
3Olaitan, A., Pashayan, N., Butler, J., Cibula, D., Costas, L., Crosbie, E.J., Falconer, H., Fotopoulou, C., Akapo, P.K., MacDonald, N., Moss, E., […] Manchanda, R., Sleigh, S and Widschwendter, M. (2026) Transforming Endometrial Cancer Diagnosis: The Case for Molecular Triage in Abnormal Uterine and Postmenopausal Bleeding. International Journal of Gynecological Cancer, p.104772.


doi: 10.1016/j.ijgc.2026.104772


Keywords: Endometrial cancer; Abnormal uterine bleeding; postmenopausal bleeding; early detection; biomarkers; DNA methhylation.
4Grube, M., Ribeiro de Souza, B., Neilson, A., Tinker, A., Staebler, A Kuzma, T., Nelson, G.S., de Kroon, C., Bosse, T., Kroep, J.R., Teo-Fortin, L., […] Hofstetter, G., Sideris, M., Manchanda, R., […] Talhouk, A., Koebel, M., Anglesio, M.S., & Kommoss, S.
Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) – a multinational team initiative. Gynecologic Oncology, 2026, 209, 48-55.

doi: https://doi.org/10.1016/j.ygyno.2026.04.008.


Keywords: Endometrioid ovarian carcinomal; Early-stage disease; Lymph node metastasis; Lymphadenectomy; Surgical staging; Adjuvant chemotherapy
5Taniskidi, A., Giannas, E., Lekka, S., Taniskidi, A., Lecoyte, A., Brincat, M., Dilley, J., Jeyarajah, A., Lawrence, A., Brockbank, E., Phadnis, S., Manchanda, R., & Sideris, M. (2026). Recurrence and Malignant Transformation After Borderline Ovarian Tumors: A Systematic Review and Meta-analysis. Anticancer Research, 46(5), 2831-2849.

doi: doi.org/10.21873/anticanres.18163


Keywords: Borderline Ovarian Tumor; Fertility-Sparing Surgery; Cystectomy; Salpingo-Oophorectomy; Recurrence; Malignant Transformation; Serous; Mucinous; Systematic Review; Meta-Analysis; Review
6Marchetti, C., Gultekin, M., Sassu, C. M., Planchamp, F., Ellis, L. B., Bowden, S., … Manchanda, R., & Kyrgiou, M. (2026). ESGO Consensus Statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome. European Journal of Cancer, 116739.

doi: 10.1016/j.ejca.2026.116739


Keywords: Lynch Syndrome; Endometrial cancer; Ovarian cancer; Screening; Risk-reducing strategy
7Malacrida, B., Elorbany, S., Laforêts, F., Karim, F., Bryan-Ravenscroft, R.C., Sideris, M., Joy, J.D., Kotantaki, P., Skingsley, S.L.P., Heath, O.M., Manchanda, R., Maniati, E., & Balkwill, F.R. 2026.
3D pentaculture model unveils malignant cell-driven macrophage polarization in high-grade serous ovarian cancer. Nature Communications.

doi: https://doi.org/10.1038/s41467-026-70398-z


Keywords: ovarian cancer; pentaculture
8Kohut, K., Turner, L., Dale, C., Duncombe, S., Gold, R., Patton, S., Stephens, R., Vale, F., White, H., Worrall, S. … Manchanda R., … Eccles, D., and Foster C., 2026. Experiences of patients and public partners in codesign of Lynch Choices™: an evaluation study using the Patient Engagement In Research Scale (PEIRS-22). Research Involvement and Engagement.

doi: doi.org/10.1186/s40900-026-00854-z


Keywords: Patient and public involvement and engagement; Codesign; Coproduction; Codevelopment; Research partnerships; Patient engagement in research scale
9Chu, K., Vidali, S., Parberry, A., Saull, M., Patel, K., Mohy‐Eldin, H., White, L., Brentnall, A., Sasieni, P., Gabe, R., Manchanda, R., Cuzick, J., Nedjai, B. 2026.
Evaluation of the Quality and Suitability of Self‐Collected Vaginal and Urine Samples for Human Papillomavirus Testing: A Prospective Matched Study. BJOG: An International Journal of Obstetrics & Gynaecology.

doi: 10.1111/1471-0528.70170


Keywords: cervical cancer; HPV; self-sampling; stability; urine; vaginal swab
10Ganesan, S., Mansour, L., Dibden, A., Sideris, M., Malan, A., Oxley, S., Kalra, A., Sia, J., Wei, X., Deshmukh, P., Mohamed, H., Morgan, R.D., Flaum, N., Brentnall, A., Fierheller, C.T., Evans, D.G., Manchanda, R.
Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology,
2026.

doi: 10.1016/j.ajog.2026.02.020


Keywords: ovarian cancer; genetic testing; NBN; meta-analysis
11Redl, E., Herzog, C., Vavourakis, C., Barrett, J., Jones, A., Evans, I., Reisel, D., Manchanda, R., Bjørge, L., Zikan, M., Cibula, D., Alkasalias, T., Flöter Rådestad, A., Gemzell-Danielsson, K., Dubeau, L., MacDonald, N., Jurkovic, D., Pashayan, N., Widschwendter, M.
The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer. International Journal of Cancer, 1-7 (2026).
1‐7.

doi:10.1002/ijc.70354REDL ET AL


Keywords: DNA, ovarian cancer, epigenetics
12Lacaze, P., Tiller, J., Brotchie, A., Nguyen-Dumont, T., Steen, J., Belluoccio, D., Young, M.A., Willis, A.M., Mitchell, L.A., Terrill, B., Nowak, K.J … Manchanda, R., … & Winship, I.
Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot. Nat. Health 1, 90–98 (2026).

DOI: 10.1038/s44360-025-00020-x


Keywords: Population genomic; pilot; feasibility
13Papalois KB, Sideris M, Oxley SG, Jeyarajah A, Lawrence A, Brockbank E, Phadnis S, Dilley J, Manchanda R.
Borderline Ovarian Tumours: A Comprehensive Review of Published Evidence. Best Practice & Research Clinical Obstetrics & Gynaecology. 2025 Nov 25:102688.

doi: 10.1016/j.bpobgyn.2025.102688


Keywords: Borderline ovarian tumours; Risk of malignancy; Treatment modality; Patient follow-up; Quality of life; Treatment guidelines
14Fierheller CT, Leung EY, Alcaraz ML, Gootzen T, Miles T, Platt MC, Sundar S, Ganesan R, Manchanda R.
Consent model for tumour genetic testing in ovarian cancer. Journal of Obstetrics and Gynaecology. 2025 Dec 31;45(1):2594629.

doi: 10.1080/01443615.2025.2594629

Keywords: Ovarian cancer; tumour genetic testing; consent
15King BG, Bharwani N, Wilson W, Cook GJ, Sohaib A, Nobbenhuis M, Warbey V, Miquel ME, Koh DM, De Paepe KN, Martin-Hirsch P, Ghaem-Maghami S, Fotopoulou C, Stringfellow H, Sundar S, Manchanda R, Sahdev A, Hackshaw A, Barwick TD, Rockall AG.

Diagnostic performance of quantitative measures from [18F] FDG PET/CT,[18F] FEC PET/CT, and DW-MRI in the detection of lymph node metastases in endometrial and cervical cancer: data from the MAPPING study. European Journal of Nuclear Medicine and Molecular Imaging. 2025 Nov 3:1-3.


doi: 10.1007/s00259-025-07587-3


Keywords: SUVmax; ADCmean; PET/CT; [18F]FDG ; [18F]fluoroethylcholine; Cervical cancer; Endometrial cancer;
Lymph node metastasis
16Sideris M, Brincat MR, Blyuss O, Oxley SG, Sia J, Kalra A, Wei X, Fierheller CT, Ganesan S, Miller RE, et al.

P-POSSUM Falls Short: Predicting Morbidity in Ovarian Cancer (OC) Cytoreductive Surgery. Cancers. 2025; 17(21):3421.

doi: 10.3390/cancers17213421

Keywords: ovarian cancer; cytoreductive surgery; P-POSSUM; surgical morbidity; morbidity prediction model
17Sia J, Lane EF, Fierheller CT, Oxley S, Kalra A, Sideris M, Wei X, Mansour L, Idahl A, Fraser H, Ganesan S, Deshmukh P, Ganesan R, Hanson H, Saridogan E, Hamed H, McCluggage WG, Legood R, Sasieni P, Evans DG, Menon U, Brentnall A, Manchanda R; PROTECTOR team.
Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer. JAMA Netw Open. 2025 Sep 2;8(9):e2532195.

doi: 10.1001/jamanetworkopen.2025.32195

Keywords: ovarian cancer, early salpingectomy, clinical effectiveness
18Laforêts F, Kotantaki P, Elorbany S, Hartlebury J, Joy JD, Malacrida B, Bryan-Ravenscroft RC, Berlato C, Di Federico E, Marshall JF, Manchanda R, Jarolimek W, Perryman L, Maniati E, Balkwill FR

Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer. bioRxiv 2025.05.19.654864

https://doi.org/10.1101/2025.05.19.654864

Keywords: ovarian cancer, microenvironment, chemotherapy
19Wei X, Mansour L, Oxley S, Fierheller CT, Kalra A, Sia J, Ganesan S, Sideris M, Sun L, Brentnall A, Duffy S, Evans DG, Yang L, Legood R, Manchanda R

Defining lifetime risk thresholds for breast cancer surgical prevention: cost-effectiveness analysis. Jama Oncol 2025

10.1001/jamaoncol.2025.2203 <

Keywords: breast cancer prevention, risk-reducing mastectomy, cost-effectiveness
20Kalra A, Ganesan S, Sia JJY, Papalois KB, Pandya A, Xiong R, Wei X, Oxley SG, Mansour L, Fierheller CT, Deshmukh PA, Mohamed H, Dibden A, Blyuss O, Sideris M, Legood R, Manchanda R.

Uptake and patient-related outcomes of mainstreaming genetic testing: a systematic review and meta-analysis. Am J Obstet Gynecol. 2025 Apr 23:S0002-9378(25)00259-5.


https://doi.org/10.1016/j.ajog.2025.04.044


Keywords: cancer; genetic testing; germline; mainstreaming; outcomes; uptake.
21Torr B, Kavanaugh G, Hamill M, Jones C, Harder H, Allen S, Garrett A, Choi S, Way R, Gold R, Taylor A, Gabe R, Lucassen A, Manchanda R, George A, Hubank M, Bremner S, Gandhi A, Kemp Z, Evans DG, Fallowfield L, Jenkins V, Turnbull C.

Uptake, utility and resource requirements of a genetic counselling telephone helpline within the BRCA-DIRECT digital pathway for mainstreamed BRCA testing in patients with breast cancer. J Med Genet. 2025 Mar 12:jmg-2024-110428.

https://jmg.bmj.com/content/early/2025/03/11/jmg-2024-110428

Keywords: Genetic Counselling; Genetic Testing; Germline Mutation; Health Services Administration; Medical Oncology.
22
Bedia JS, Jacobs IJ, Ryan A, Gentry-Maharaj A, Burnell M, Singh N, Manchanda R, Kalsi JK, Dawnay A, Fallowfield L, McGuire A, Campbell S, Parmar MKB, Menon U, Skates SJ.


Estimating the Ovarian Cancer CA-125 Preclinical Detectable Phase, In-Vivo Tumour Doubling Time, and Window for Detection in Early Stage: An Exploratory Analysis of UKCTOCS. EBioMedicine. 2025 Feb;112:105554

https://doi.org/10.1016/j.ebiom.2024.105554

Keywords: CA-125 antigen, Blood, Carcinoma, Ovarian epithelial∗, Early detection of cancer∗, Longitudinal studies, Ovarian neoplasms∗, Epidemiology, UKCTOCS, Mass screening, Biomarker, Preclinical history of cancer, Preclinical detectable phase, Natural history of cancer, Early diagnosis
23Torr B, Bell N, McCarthy R, Hamill M, Nolan J, Muralidharan S, Andrews C, Valganon-Petrizan M, Clinch Y, MacMahon S, Morilla A, George A, Ryves P, Dasani P, Adegoroye M, Schlecht H, Burghel GJ, Ornadel W, Gordon N, Steele L, Lukic S, Watts E, Evans DG, Manchanda R, Turnbull C.

The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023-2024). J Med Genet. 2025 Jan 27;62(2):69-73.

https://jmg.bmj.com/content/62/2/69.long

Keywords: Genetic Testing; Genetics, Population; Policy; Public Health.
24Fotopoulou C, Bowen R, Manchanda R, Michael A, McCormack S, Ullmann A, Wesselbaum A, Levick B, Miller R
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023). Future Oncol. 2025 Jan;21(1):95-103.
https://doi.org/10.1080/14796694.2024.2424153

Keywords: BRCA; OC-NOW; PARP inhibitors; biomarker; management; ovarian cancer.
25Elorbany S, Berlato C, Carnevalli LS, Maniati E, Barry ST, Wang J, Manchanda R, Kzhyshkowska J, Balkwill F.
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer. Nat Commun. 2024 Nov 22;15(1):10144

https://www.nature.com/articles/s41467-024-54295-x

Keywords: ovarian cancer, immunotherapy
26Ng, Z.Y, Manchanda, R, Lopez, A, Obermair, A, Dostalek, L., Pareja, R, van Lonkhuijzen, L.R.C.W, Falconer, H, Ortiz, D.I, Fagotti, A, Ramirez, P.T, Landoni, F, Weinberger, V, Laky, R, Kim, S.H, Klat, J, Kocian, R, Pari, D, Borcinova, M, Nemejcova, K, Cibula, D.
The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study. Gynecol Oncol 2024, 191, 95-99

https://doi.org/10.1016/j.ygyno.2024.09.022

Keywords: cervical cancer, recurrence,
27
Taylor A; Clement K; Hillard T; Sassarini J; Ratnavelu N; Baker-Rand H; Bowen R; Davies M; Edey K; Fernandes A; Ghaem-Maghami S; Gomes N; Gray S; Hughes E; Hudson A; Manchanda R ; Manley K; Nicum S; Phillips A; Richardson A; Morrison J.
British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer. Post Reprod Health. 2024 Dec;30(4):256-279.

https://doi.org/10.1177/20533691241286666
Keywords: menopause, gynaecological cancer
28
Oxley S, Ahmed S, Baxter K, Blake D, Braden V, Brincat MR, Bryan S, Dilley J, Dobbs S, Durden A, Gomes N, Johnston B, Kaushik S, Kokka F, Lockley M, Lowe-Zinola J, Manchanda R, McCormick A, Nott C, Owens G, Pandya A, Prince J, Ryan N, Ryan N, Sideris M, Tanna S, Waters J, Zamesa N, Thomas M*, Olaitan A.
Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2024 Nov ;34(11):1768-1774.
https://doi.org/10.1136/ijgc-2024-005742

Keywords: venous thromboembolism, VTE, chemotherapy, ovarian cancer
29
*Sun L, *Wei X, *Fierheller CT, Dawson L, Oxley S, Kalra A, Sia J, Feldman F, Peacock S, Schrader KA, Legood R, Kwon JS, Manchanda R
Economic Evaluation of Population-based BRCA1 and BRCA2 Testing in Canada. JAMA Netw Open. 2024;7(9):e2432725
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823637

Keywords: cost-effectiveness, BRCA1, BRCA2, population testing
30
Elaine Leung, Shibani Nicum, Jo Morrison, James Brenton, Gabriel Funingana, Robert Morgan, Sadaf Ghaem-Maghami, Tracie Miles, Ranjit Manchanda, Rebecca Bowen, Adrian Andreou, Will Loughborough, Sue Freeman, Ketan Gajjar, Sarah Coleridge, Mercedes Jimenez-Linan, Janos Balega, Jonathan Frost, Amy Keightley, Yvonne Wallis, Sudha Sundar and Raji Ganesan.
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom. Int J Gynecol Cancer 2024;
https://ijgc.bmj.com/content/34/9/1334 doi:10.1136/ijgc-2024-005756

Keywords: BRCA1 protein, BRCA2 protein, homologous recombination, neoplasms, ovarian cancer
31
Gootzen, T.A.; Kalra, A.; Sarig, K.; Sobočan, M.; Oxley, S.G.; Dworschak, N.; Georgiannakis, A.; Glynou, S.; Taniskidi, A.; Ganesan, S.; Ferris, M.; Legood, R.; Eeles, R.; Evans, D.G.R.; Fierheller, C.T.; Manchanda, R.
Online Provision of BRCA1 and BRCA2 Health Information: A Search Engine Driven Systematic Web-Based Analysis. Cancers 2024, 16, 2324;
https://doi.org/10.3390/cancers16132324

Keywords: BRCA, Jewish, genetic testing, online information
32
Moss E, Taylor A, Andreou A, Ang C, Arora R, Attygalle A, Banerjee S, Bowen R, Buckley L, Burbos N, Coleridge S, Edmondson R, El-Bahrawy M, Fotopoulou C, Frost J, Ganesan R, George A, Hanna L, Kaur, Manchanda R, Maxwell H, Michael A, Miles T, Baljeet N, Nicum S, Ratnavelu N, Ryan, Sundar S, Vroobel K, Walther A, Wong J, Morrison J.
British Gynaecological Cancer Society (BGCS) Ovarian, Tubal and Primary Peritoneal Cancer Guidelines: Recommendations for Practice Update 2024. Eur J Obs Gynae Reprod Biol 2024;

https://doi.org/10.1016/j.ejogrb.2024.06.025

Keywords: chemotherapy, cytoreductive surgery, epithelial ovarian carcinoma, fallopian tube cancer, germ cell tumour, granulosa cell tumour, NACT, ovarian cancer
33
Manchanda R, Sun L, Sobocan M, Rodriguez IV, Wei X, Kalra A, Oxley S, Sideris M, Fierheller CT, Morgan RD, Chandrasekaran D, Rust K, Spiliopoulou P, Miller RE, Crusz SM, Lockley M, Singh N, Faruqi A, Casey L, Brockbank E, Phadnis S, Mills-Baldock T, El-Khouly F, Jenkins LA, Wallace A, Ahmed M, Kumar A, Swisher EM, Gourley C, Norquist BM, Evans DG, Legood R.
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer. J Natl Compr Canc Netw. 2024 Apr 18;22(2D):e237331.
https://jnccn.org/view/journals/jnccn/22/2D/article-e237331.xml

Keywords: cost-effectiveness, unselected, multigene testing, ovarian cancer
34
Joy JD, Malacrida B, Laforets F, Kotantaki P, Maniati E, Manchanda R, Annibaldi A, Hopkins S, Garrobo-Calleja I, Gautrot J, Balkwill FR. Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity. Cancer Res. 2024 May 31. Epub ahead of print.
https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-23-3007/745591/Human-3D-ovarian-cancer-models-reveal-malignant

Keywords: ovarian cancer, immune cell therapy, CAR T cell, 3D human cell model
35
Slade E, Berg L, Dworzynski K, Manchanda R; Guideline Committee. Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance. BMJ. 2024 May 9;385:q807.
https://www.bmj.com/content/385/bmj.q807.long

Keywords: ovarian cancer, genetic testing, risk assessment
36
Newton C, Graham R, Liberale V, Burnell M, Menon U, Mould T, Olaitan A, Macdonald N, Widschwendter M, Doufekas K, McCormack M, Mitra A, Arora R, Manchanda R. Outcomes of minimal access retroperitoneal para-aortic lymphadenectomy in patients with locally advanced cervical cancer. J Obstet Gynaecol. 2024 Dec;44(1):2344529.
https://www.tandfonline.com/doi/full/10.1080/01443615.2024.2344529

Keywords: cervical cancer, lymphadenectomy

37
Oxley SG, Wei X, Sideris M, Blyuss O, Kalra A, Sia JJY, Ganesan S, Fierheller CT, Sun L, Sadique Z, Jin H, Manchanda R, Legood R. Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D. Cancers (Basel). 2024 Mar 30;16(7):1358.
https://www.mdpi.com/2072-6694/16/7/1358

Keywords: mapping; risk-reducing mastectomy; risk-reducing salpingo-oophorectomy; utility scores

38
Sarig K, Oxley S, Kalra A, Sobocan M, Fierheller CT, Sideris M, Gootzen T, Ferris M, Eeles RA, Evans DG, Quaife SL, Manchanda R. BRCA awareness and testing experience in the UK Jewish population: a qualitative study. J Med Genet. 2024 Apr 4:jmg-2023-109576.
https://jmg.bmj.com/content/early/2024/04/04/jmg-2023-109576.long

Keywords: Genetic Testing; Genetics, Population; Health Care Quality, Access, and Evaluation; Women’s Health

39
Sideris M, Menon U, Manchanda R. Screening and prevention of ovarian cancer. Med J Aust. 2024 Mar 18;220(5):264-274.
https://onlinelibrary.wiley.com/doi/10.5694/mja2.52227

Keywords: Mass screening; Ovarian neoplasms; Preventive medicine.

40
Wei X, Sun L, Slade E, Fierheller CT, Oxley S, Kalra A, Sia J, Sideris M, McCluggage WG, Bromham N, Dworzynski K, Rosenthal AN, Brentnall A, Duffy S, Evans DG, Yang L, Legood R, Manchanda R. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. JAMA Netw Open. 2024 Feb 5;7(2):e2355324.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2814870

Keywords: ovarian cancer, breast cancer, prevention, cost-effectiveness, cancer genetics

41
Lakhiani A, Cummins C, Kumar S, Long J, Arora V, Balega J, Broadhead T, Duncan T, Edmondson R, Fotopoulou C, Glasspool R, Kolomainen D, Manchanda R, McNally O, Morrison J, Mukhopadhyay A, Naik R, Wood N, Sundar S. Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer-Quality of Life Evaluation Research) Prospective, International, Multicentre Study. Cancers (Basel). 2023 Dec 22;16(1):75.
https://www.mdpi.com/2072-6694/16/1/75

Keywords: anxiety; depression; fear of progression; ovarian cancer; quality of life

42
Lacaze P, Marquina C, Tiller J, Brotchie A, Kang YJ, Merritt MA, Green RC, Watts GF, Nowak KJ, Manchanda R, Canfell K, James P, Winship I, McNeil JJ, Ademi Z. Combined population genomic screening for three high-risk conditions in Australia: a modelling study. EClinicalMedicine. 2023 Nov 8;66:102297.
https://www.sciencedirect.com/science/article/pii/S2589537023004741

Keywords: Cost-effectiveness analysis; Genomic testing; Genomics; Health-economic evaluation; Population screening; Prevention; Public health

43
Gaba F, Blyuss O, Chandrasekaran D, Bizzarri N, Refky B, Barton D, Ind T, Nobbenhuis M, Butler J, Heath O, Jeyarajah A, Brockbank E, Lawrence A, Manchanda R, Dilley J, Phadnis S, On Behalf Of The Go Soar Collaborative. Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2023 Nov 20;13(22):3484.
https://www.mdpi.com/2075-4418/13/22/3484

Keywords: diagnostics; ovarian cancer; prognosis; recurrence; surgery

44
Dilley J, Gentry-Maharaj A, Ryan A, Burnell M, Manchanda R, Kalsi J, Singh N, Woolas R, Sharma A, Williamson K, Mould T, Fallowfield L, Campbell S, Skates SJ, McGuire A, Parmar M, Jacobs I, Menon U. Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer – An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2023 Dec;179:123-130.
https://www.sciencedirect.com/science/article/pii/S0090825823015329

Keywords: GOFF index; NICE; Ovarian cancer; Symptoms; UKCTOCS

45
Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Fierheller C, Kalra A, Sia J, Miller RE, Mills-Baldock T, Crusz SM, Sun L, Evans O, Robbani S, Jenkins LA, Ahmed M, Kumar A, Quigley M, Lockley M, Faruqi A, Casey L, Brockbank E, Phadnis S, Trevisan G, Singh N, Legood R, Manchanda R. Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study. BJOG. 2023 Sep 26. doi: 10.1111/1471-0528.17675.
https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17675

Keywords: Decision aids; genetic testing; mainstreaming; ovarian cancer

46
Wei X, Oxley S, Sideris M, Legood R, Manchanda R. Patient-reported quality of life following prophylactic surgery for breast and ovarian cancer prevention: response. Am J Obstet Gynecol. 2024 Feb;230(2):274-275.
https://www.sciencedirect.com/science/article/pii/S0002937823005987

Keywords: quality of life, prevention, breast cancer, ovarian cancer

47
Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Singh N, Manchanda R, Kalsi JK, Woolas R, Arora R, Casey L, Dawnay A, Sharma A, Williamson K, Apostolidou S, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar MKB. Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. Lancet Oncol. 2023 Sep;24(9):1018-1028. doi: 10.1016/S1470-2045(23)00335-2. Erratum in: Lancet Oncol. 2024 Feb;25(2):e61.
https://www.sciencedirect.com/science/article/pii/S1470204523003352

Keywords: ovarian cancer, UKCTOCS, screening, survival

48
Bizzarri N, Querleu D, Dostalek L, van Lonkhuijzen LRCW, Giannarelli D, Lopez A, Salehi S, Ayhan A, Kim SH, Ortiz DI, Klat J, Landoni F, Pareja R, Manchanda R, Kostun J, Ramirez PT, Meydanli MM, Odetto D, Laky R, Zapardiel I, Weinberger V, Dos Reis R, Pedone Anchora L, Amaro K, Akilli H, Abu-Rustum NR, Salcedo-Hernandez RA, Javurkova V, Mom CH, Scambia G, Falconer H, Cibula D. Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study. Am J Obstet Gynecol. 2023 Oct;229(4):428.e1-428.e12.
https://www.sciencedirect.com/science/article/pii/S0002937823004222

Keywords: cervical cancer; early stage; laparotomy; radical hysterectomy; radicality; surgery; survival.

49
Pillai D, Narayan J, Gentry-Maharaj A, Deo S, Vijaykumar DK, Mukherjee P, Wadhwa N, Bhasin A, Mishra A, Rajanbabu A, Kannan R, Husain Z, Kumar A, Antoniou AC, Manchanda R, Menon U. Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in India. Cancers (Basel). 2023 May 30;15(11):2973
https://www.mdpi.com/2072-6694/15/11/2973

Keywords: LMIC; breast cancer; patient and public involvement; risk communication; risk representation; transmedia tools

50Laforets F, Kotantaki P, Malacrida B, Elorbany S, Manchanda R, Donnadieu E, Balkwill F. Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. iScience. 2023 Mar 29;26(4):106514.
https://www.sciencedirect.com/science/article/pii/S2589004223005916

Keywords: Cancer; Immunology; Microenvironment
51
Morgan RD, Clamp AR, Barnes BM, Timms K, Schlecht H, Yarram-Smith L, Wallis Y, Valganon-Petrizan M, MacMahon S, White R, Morgan S, McKenna S, Hudson E, Tookman L, George A, Manchanda R, Sundar SS, Nicum S, Brenton JD, Kristeleit RS, Banerjee S, McNeish IA, Ledermann JA, Taylor SS, Evans DGR, Jayson GC. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. Int J Gynecol Cancer. 2023 Aug 7;33(8):1253-1259.
https://ijgc.bmj.com/content/33/8/1253

Keywords: BRCA1 Protein; BRCA2 Protein; Homologous recombination; Ovarian Cancer
52
Wei X, Oxley S, Sideris M, Kalra A, Brentnall A, Sun L, Yang L, Legood R, Manchanda R. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023 Oct;229(4):388-409.e4.
https://www.sciencedirect.com/science/article/pii/S0002937823002405

Keywords: breast cancer; meta-analysis; ovarian cancer; quality of life; risk-reducing surgery.
53
Gaba F, Blyuss O, Tan A, Munblit D, Oxley S, Khan K, Legood R, Manchanda R. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023 Mar 6;15(5):1625
https://www.mdpi.com/2072-6694/15/5/1625

Keywords: BRCA; breast cancer; meta-analysis; risk-reducing salpingo-oophorectomy.
54
Oxley S, Kalra A, Sideris M, Itzkowitz N, Evans O, Atakpa EC, Brentnall AR, Dworschak N, Gaba F, Gabe R, Sundar S, Wood N, Nicum S, Taylor A, Dobbs S, McCluggage WG, Nordin A, Legood R, Kehoe S, Ghaem-Maghami S, Manchanda R. Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UK. Cancers (Basel). 2023 Feb 16;15(4):1273
https://www.mdpi.com/2072-6694/15/4/1273

Keywords: COVID-19; gynaecological cancer; multidisciplinary team
55
Bizzarri N, Dostalek L, van Lonkhuijzen LRCW, Giannarelli D, Lopez A, Falconer H, Querleu D, Ayhan A, Kim SH, Ortiz DI, Klat J, Landoni F, Rodriguez J, Manchanda R, Kostun J, Ramirez PT, Meydanli MM, Odetto D, Laky R, Zapardiel I, Weinberger V, Dos Reis R, Pedone Anchora L, Amaro K, Salehi S, Akilli H, Abu-Rustum NR, Salcedo-Hernandez RA, Javurkova V, Mom CH, Scambia G, Cibula D. Association of Hospital Surgical Volume With Survival in Early-Stage Cervical Cancer Treated With Radical Hysterectomy. Obstet Gynecol. 2023 Jan 1;141(1):207-214.
https://journals.lww.com/greenjournal/fulltext/2023/01000/association_of_hospital_surgical_volume_with.23.aspx

Keywords: cervical cancer, survival, surgical volume, radical hysterectomy
56
Lacaze P, Manchanda R, Green RC. Prioritizing the detection of rare pathogenic variants in population screening. Nat Rev Genet. 2023 Apr;24(4):205-206
https://www.nature.com/articles/s41576-022-00571-9

Keywords: population screening, genetic testing, polygenic risk score
57
Wei X, Oxley S, Sideris M, Kalra A, Sun L, Yang L, Legood R, Manchanda R. Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review. Cancers (Basel). 2022 Dec 12;14(24):6117.
https://www.mdpi.com/2072-6694/14/24/6117

Keywords: BRCA; breast cancer; cost-effectiveness; ovarian cancer; risk-reducing surgery
58
Oxley S, Xiong R, Wei X, Kalra A, Sideris M, Legood R, Manchanda R. Quality of Life after Risk-Reducing Hysterectomy for Endometrial Cancer Prevention: A Systematic Review. Cancers (Basel). 2022 Nov 26;14(23):5832.
https://www.mdpi.com/2072-6694/14/23/5832

Keywords: Lynch syndrome; decision regret; endometrial cancer prevention; hysterectomy; menopause; quality of life; risk reducing hysterectomy; satisfaction
59
Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees; Lalloo F. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. J Med Genet. 2023 May;60(5):417-429.
https://jmg.bmj.com/content/60/5/417

Keywords: Clinical Decision-Making; Delivery of Health Care; Genetic Carrier Screening; Genetic Predisposition to Disease; Gynaecology
60
Gaba F, Ash K, Blyuss O, Bizzarri N, Kamfwa P, Ramirez PT, Kotsopoulos IC, Chandrasekaran D, Gomes N, Butler J, Nobbenhuis M, Ind T, Heath O, Barton D, Jeyarajah A, Brockbank E, Lawrence A, Dilley J, Manchanda R, Phadnis S, Soar GO. Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative). Int J Gynecol Cancer. 2022 Dec 5;32(12):1606-1610.
https://ijgc.bmj.com/content/32/12/1606

Keywords: Ovarian Cancer; Surgery
61
Yong N, Cooper N, Yorke S, Baran C, Khan K, Tan A, Sideris M, Iliodromiti S, Manchanda R. Variation in outcome reporting in studies of fertility-sparing surgery for cervical cancer: A systematic review. BJOG. 2023 Jan;130(2):163-175.
https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17342

Keywords: cervical cancer; core outcomes; fertility-sparing
62
Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J, Ahmed M, Edmondson R, Woodward ER, Lamnisos A, Balega J, Brady AF, Sharma A, Izatt L, Kulkarni A, Tripathi V, Solomons JS, Hayes K, Hanson H, Snape K, Side L, Skates S, McGuire A, Rosenthal AN. The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2. J Med Genet. 2023 May;60(5):440-449.
https://jmg.bmj.com/content/60/5/440

Keywords: Costs and Cost Analysis; Early Diagnosis; Economics; Genetic Predisposition to Disease; Women’s Health
63
Cummins C, Kumar S, Long J, Balega J, Broadhead T, Duncan T, Edmondson RJ, Fotopoulou C, Glasspool RM, Kolomainen D, Leeson S, Manchanda R, Morrison J, Naik R, Tidy JA, Wood N, Sundar S. Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study. Cancers (Basel). 2022 Sep 7;14(18):4362.
https://www.mdpi.com/2072-6694/14/18/4362

Keywords: cytoreduction; ovarian cancer; population analysis; radical; surgical complexity; survival; ultra-radical
64
Sun L, Wei X, Manchanda R*, Legood R*, Yang L*. Using Genetic Testing at Cancer Diagnosis for Breast Cancer Control. China CDC Wkly. 2022 Aug 12;4(32):711-714.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433755/ (*equal contribution)

Keywords: breast cancer, China, genetic testing, risk-reducing strategies
65
Manchanda R, Sideris M. Population-based genetic testing for cancer susceptibility genes: quo vadis? BJOG. 2023 Jan;130(2):125-130
https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17283

Keywords: population screening, genetic testing, ovarian cancer, breast cancer, endometrial cancer, colorectal cancer
66
Tindale LC, Zhantuyakova A, Lam S, Woo M, Kwon JS, Hanley GE, Knoppers B, Schrader KA, Peacock SJ, Talhouk A, Dummer T, Metcalfe K, Pashayan N, Foulkes WD, Manchanda R, Huntsman D, Stuart G, Simard J, Dawson L. Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention. Curr Oncol. 2022 Jun 30;29(7):4632-4646.
https://www.mdpi.com/1718-7729/29/7/368

Keywords: BRCA; cancer screening; hereditary cancer syndrome; population-based genetic testing
67
Torr B, Jones C, Choi S, Allen S, Kavanaugh G, Hamill M, Garrett A, MacMahon S, Loong L, Reay A, Yuan L, Valganon Petrizan M, Monson K, Perry N, Fallowfield L, Jenkins V, Gold R, Taylor A, Gabe R, Wiggins J, Lucassen A, Manchanda R, Gandhi A, George A, Hubank M, Kemp Z, Evans DG, Bremner S, Turnbull C. A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot. J Med Genet. 2022 Dec;59(12):1179-1188.
https://jmg.bmj.com/content/59/12/1179

Keywords: genetic counseling; genetic predisposition to disease; genetic testing; genetics; health care facilities, manpower, and services
68
Burnell M, Gaba F, Sobocan M, Desai R, Sanderson S, Loggenberg K, Gessler S, Side L, Brady A, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R. Randomised trial of population based BRCA testing in Ashkenazi Jews: Long term secondary lifestyle behavioural outcomes. BJOG 2022; https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/1471-0528.17253

Keywords: Ashkenazi Jews, BRCA1/BRCA2, cancer risk, genetic testing, lifestyle, population testing
69
Tindale LC, Zhantuyakova A, Lam S, Woo M, Kwon JS, Hanley GE, Knoppers B, Schrader KA, Peacock SJ, Talhouk A, Dummer T, Metcalfe K, Pashayan N, Foulkes WD, Manchanda R, Huntsman D, Stuart G, Simard J, Dawson L. Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention. Current Oncology. 2022; 29(7):4632-4646. https://doi.org/10.3390/curroncol29070368

Keywords: cancer screening; hereditary cancer syndrome; population-based genetic testing; BRCA
70
Gaba F, Oxley S, Liu X, Yang X, Chandrasekaran D, Kalsi J, Antoniou A, Side L, Sanderson S, Waller J, Ahmed M, Wallace A, Wallis Y, Menon U, Jacobs I, Legood R, Marks D, Manchanda R. Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. Diagnostics. 2022; 12(5):1028. https://doi.org/10.3390/diagnostics12051028

Keywords: ovarian cancer; population testing; risk stratification; health and well-being
71
Sun L, Cui B, Wei X, Sadique Z, Yang L, *Manchanda R, *Legood R. Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China. Cancers. 2022; 14(7):1839. https://doi.org/10.3390/cancers14071839 (*equal contribution)

Keywords: breast cancer; genetic testing; screening; cost-effectiveness analysis
72
Taylor, A., Sundar, S. S., Bowen, R., Clayton, R., Coleridge, S., Fotopoulou, C., Ghaem-Maghami, S., Ledermann, J., Manchanda, R., Maxwell, H., Michael, A., Miles, T., Nicum, S., Nordin, A., Ramsay, B., Rundle, S., Williams, S., Wood, N. J., Yiannakis, D., & Morrison, J. “British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.” Obstetrical & Gynecological Survey: 2022; 77 (3): 156-157. doi:10.1097/01.ogx.0000822432.56370.10

Keywords: Covid-19, gynaecological oncology care, BGCS
73
Barrett J.E., Jones A., Evans I, Reisel D, Herzog C, Chindera K, Kristiansen M, Leavy OC, Manchanda R, Bjorge L, Zikan M, Cibula D, Widschwendter M. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nat Commun 13, 448 (2022). https://doi.org/10.1038/s41467-021-26615-y

Keywords: DNA methylome, ovarian cancer, biomarkers, cancer prevention
74
Sundar, S, Cummins, C, Kumar, S, Long, J, Arora, V, Balega, J, Tim Broadhead, Tim Duncan, Richard Edmondson, Christina Fotopoulou, Ros Glasspool, Desiree Kolomainen, Simon Leeson, Manchanda R, McNally O, Morrison J, Mukhopadhyay A, Paul J, Tidy J, Wood N. Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. BJOG: Int J Obstet Gy. 2022; 00: 1– 11. https://doi.org/10.1111/1471-0528.17041

Keywords: extensive surgery, ovarian cancer, quality of life, ultraradical surgery
75
Cibula D, Dostalek L, Jarkovsky J, Mom CH, Lopez A, Falconer H, Scambia G, Ayhan A, Kim SH, Isla Ortiz D, Klat J, Obermair A, Di Martino G, Pareja R, Manchanda R, Kostun J, dos Reis R, Meydanli MM, Odetto D, Laky R, Zapardiel I, Weinberger V, Benesova K, Borcinova M, Cardenas F, Wallin E, Pedone Anchora L, Akilli H, Abu-Rustum NR, Barquet-Munoz SA, Javurkova V, Fischerova D, van Lonkhuijzen LRCW. Post-recurrence survival in patients with cervical cancer. Gynecol Oncol, 2021; https://doi.org/10.1016/j.ygyno.2021.12.018

Keywords: Early-stage cervical cancer, Recurrence, Post-recurrence disease-specific survival, Prognosis, Multivariable model, Risk profile
76
Taylor, A., Sundar, S. S., Bowen, R., Clayton, R., Coleridge, S., Fotopoulou, C., Ghaem-Maghami, S., Ledermann, J., Manchanda, R., Maxwell, H., Michael, A., Miles, T., Nicum, S., Nordin, A., Ramsay, B., Rundle, S., Williams, S., Wood, N. J., Yiannakis, D., & Morrison, J. “British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.” Int J Gynecol Cancer. 2021. Epub 2021/11/20. doi: 10.1136/ijgc-2021-002942. PubMed PMID: 34795019

Keywords: Covid-19, gynaecological oncology care, BGCS
77
Reisel D, Burnell M, Side L, Loggenberg K, Gessler S, Desai R, Sanderson S, Brady A, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R. Jewish Cultural and Religious factors and uptake of Population based BRCA testing across denominations: a cohort study. BJOG 2021; https://doi.org/10.1111/1471-0528.16994

Keywords: Ashkenazi-Jewish,BRCA, cultural, denomination,population-based, religious
78
Manchanda R, Gaba F, Talaulikar V, Pundir J, Gessler S, Davies M, Menon U, on behalf of the Royal College of Obstetricians and Gynaecologists. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause. RCOG Scientific Impact Paper No. 66. BJOG 2021; https://doi.org/10.1111/1471-0528.16896.

Keywords: Risk-reducing surgery, hormone replacement therapy, menopause, salpingo-oophorectomy, scientific impact paper
79
Lee A, Yang X, Tyrer J, Gentry-Maharaj A, Ryan A, Mavaddat N, Cunningham AP, Carver T, Archer S, Leslie G, Kalsi J, Gaba F, Manchanda R, Gayther SA, Ramus SJ, Walter FM, Tischkowitz M,
Jacobs I, Menon U, Easton DF, Pharoah PPD, Antoniou AC. A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors. J Med Genet 2021; http://dx.doi.org/10.1136/jmedgenet-2021-107904

Keywords: Risk prediction model, risk stratification, ovarian cancer, CanRisk Tool, synthetic model approach
80
Cibula D, Dostalek L, Jarkovsky J, Mom CH, Lopez A, Falconer H, Fagotti A, Ayhan A, Kim SH, Ortiz DI, Klat J, Obermair A, Landoni F, Rodriguez J, Manchanda R, Kostun J, dos Reis R, Meydanli MM, Odetto D, Laky R, Zapardiel I, Weinberger V, Benesova J, Borcinova M, Pari D, Salehi S, Bizzarri N, Akilli H, Abu-Rustum NR, Salcedo-Hernandez RA, Javurkova V, Slama J, van Lonkhuijzen LRCW. The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer. Eur J Cancer 2021; 158: 111-122. https://doi.org/10.1016/j.ejca.2021.09.008

Keywords: Cervical cancer, Surveillance, Prognostic model, Annual recurrence risk
81
Rockall A, Barwick T, Wilson W, Singh N, Bharwani N, Sohaib A, Nobbenhuis M, Warbey V, Miquel M, Koh DM, DePaepe K, Martin-Hirsch P, Ghaem-Maghami S, Fotopoulou C, Stringfellow H, Sundar S, Manchanda R, Sahdev A, Hackshaw A, Cook G, and MAPPING Group. Diagnostic accuracy of FEC-PET/CT, FDG-PET/CT and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma. Clinical Cancer Res 2021; https://clincancerres.aacrjournals.org/content/early/2021/09/14/1078-0432.CCR-21-1834

Keywords: MAPPING, diagnostic accuracy, nodal metastases, FEC-PET/CT, FDG-PET/CT
82
Manchanda R, Oxley S, Ghaem-Maghami S, Sundar S. COVID-19 and the impact on gynecologic cancer care. Int J Gynecol Obstet 2021; 155(Suppl. 1):94–101. DOI: 10.1002/ijgo.13868
83
Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L, Hammond RFL, Gaba F, Jenkins LA, Ahmed M, Kumar A, Jeyarajah A, Lawrence AC, Brockbank E, Phadnis S, Quigley M, El Khouly F, Wuntakal R, Faruqi A, Trevisan G, Casey L, Burghel GJ, Schlecht H, Bulman M, Smith P, Bowers NL, Legood R, Lockley M, Wallace A, Singh N, Evans DG, Manchanda R. Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study. Cancers 2021; 13 (17), 4344. https://doi.org/10.3390/cancers13174344 PMID: 34503154; PMCID: PMC8431198

Keywords: ovarian cancer; BRCA; genetic testing; germline; somatic; RAD51C; RAD51D; BRIP1
84
Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA, Gaarenstroom KN, Slangen BFM, Vergote I, Brannstrom M, van Dorst EBL, van Driel WJ, Hermans RH, Nunns D, Widschwendter M, Nugent D, Holland CM, Sharma A, DiSilvestro PA, Mannel R, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB, Luesley D, Ellis P, Duncan TJ, Tjiong MY, Cruickshank DJ, Kjolhede P, Levenback CF, Bouda J, Kieser KE, Palle C, Spirtos NM, O’Malley DM, Leitao MM, Geller MA, Dhar K, Asher V, Tamussino K, Tobias DH, Borgfeldt C, Lea JS, Bailey J, Lood M, Eyjolfsdottir B, Attard-Montalto S, Tewari KS, Manchanda R, Jensen PT, Persson P, Van Le L, Putter H, de Bock GH, Monk BJ, Creutzberg CL, van der Zee AGJ. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. J Clin Oncol. 2021 Aug 25:JCO2100006. doi: 10.1200/JCO.21.00006. Epub ahead of print. PMID: 34432481.

Keywords: GROINSS-V II, groin lymphadenectomy, radiotherapy, vulvar cancer, sentinel node, clinical trial, inguinofemoral lymphadenectomy
85
Taylor, JA; Burnell, M; Ryan, A; Karpinskyj, C; Kalsi, J; Taylor, H; Apostolidou, S; Sharma, A; Manchanda, R; Woolas, R; Campbell, S; Parmar, M; Singh, N ; Jacobs, IJ; Menon, U; Gentry-Maharaj, A. Association of hysterectomy and invasive epithelial ovarian and tubal cancer: A cohort study within UKCTOCS. BJOG 2021; https://doi.org/10.1111/1471-0528.16943

Keywords: Hysterectomy, ovarian cancer, ovarian neoplasm, risk,type, UKCTOCS.
86

Reisel D, Baran C, Manchanda R. Preventive population genomics- the model of BRCA related cancers. Advances in Genetics, 2021; https://doi.org/10.1016/bs.adgen.2021.08.001

Keywords: Population testing, Genomics, BRCA, SNPs, Cancer prevention, Screening, Precision prevention
87
Gaba F, Blyuss O, Rodriguez I, Dilley J, Wan YLL, Saiz A, Razumova Z, Zalewski K, Nikolova T, Selcuk I, Gaba F, Theofanakis C, Lanner M, Pletnev A, Gurumurthy M, Manchanda R. Impact of SARS-CoV-2 on training and mental well-being of surgical gynecological oncology trainees. Int J Gynecol Cancer 2021; doi: 10.1136/ijgc-2021-002803

Keywords: COVID-19, gynaecological oncology training, mental well-being, survey, cross-sectional study
88
Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, Kalsi JK, Woolas R, Manchanda R, Arora R, Casey L, Dawnay A, Dobbs S, Leeson S, Mould T, Seif MW, Sharma A, Williamson K, Liu Y, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar M. General population screening and ovarian cancer mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2021, doi: 10.1016/S0140-6736(21)00731-5

Keywords: UKCTOCS, randomised controlled trial, screening, ovarian cancer, mortality
89
Gaba F, Goyal S, Marks D, Chandrasekaran D, Evans, O, Robbani S, Tyson C, Legood R, Saridogan E, McCluggage GW, Hanson H, Singh N, Evans DG, Menon U, Manchanda R, on behalf of the PROTECTOR team. Surgical decision making in premenopausal BRCA carriers considering risk reducing early-salpingectomy or salpingo-oophorectomy: a Qualitative Study. J Med Genet 2021; 0:1–11. doi:10.1136/jmedgenet-2020-107501

Keywords: Study protocol, PROTECTOR, risk reducing surgery, qualitative research
90
Kriplani D, Olivar AA, Tchrakian N, Butcher D, Casey L, Crook JA, Deo N, Dilley J, Griffiths R, Hogg M, Jeyarajah AR, Khan SJ, Lawrence A, Lee A, Leen SL, Leitch-Devlin L, Manchanda R, Masood M, Nyarko E, Okaro E, Phadnis S, Trevisan G, Tsang J, Vimplis S, Wilmott F, Brockbank E, Singh N. Concise Reporting of Benign Endometrial Biopsies is an Acceptable Alternative to Descriptive Reporting. Int J Gynecol Pathol 2021; DOI: 10.1097/PGP.0000000000000761

Keywords: Endometrial biopsy, Template reporting, Interobserver reproducibility.,
91
Sundar S, Manchanda R, Gourley C, George A, Wallace A, Balega J, Williams S, Wallis Y, Edmondson R, Nicum S, Frost J, Attygalle A, Fotopoulou C, Bowen R, Bell D, Gajjar K, Ramsay B, Wood N, Ghaem-Maghami S, Miles T, Ganesan R. British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumour testing for BRCA1/2 variants in ovarian cancer in the United Kingdom. Int J Gynecol Cancer 2021;0:1–7. doi:10.1136/ijgc-2020-002112; PMID: 33468564

Keywords: Consensus guideline, germline testing, tumor testing, BGCS, BRCA1, BRCA2, BAGP
92
Gallagher A, Waller J, Manchanda R, Jacobs I, Sanderson S. Women’s intentions to engage in risk-reducing behaviours after receiving personal ovarian cancer risk information: an experimental survey study. Cancers (Basel) 2020; 12(12), 3543; https://doi.org/10.3390/cancers12123543

Keywords: risk stratification; genomics; questionnaires; attitudes
93
Gaba F, Robbani S, Singh N, McCluggage GW, Wilkinson N, Ganesan R, Bryson G, Rowlands G, Tyson C, Arora R, Saridogan E, Hanson H, Burnell M, Legood R, Evans DG, Menon U, Manchanda R, on behalf of the PROTECTOR team. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multicentre trial. Int J Gynecol Cancer 2020; http://dx.doi.org/10.1136/ijgc-2020-001541 PMID: 32907814

Keywords: PROTECTOR, study protocol, risk reducing surgery, early salpingectomy, delayed oophorectomy
94
Gaba F, Blyuss O, Chandrasekaran D, Osman M, Goyal S, Gan C, Izatt L, Tripathi V, Esteban I, McNicol L, Ragupathy K, Crawford R, Evans DG, Legood R, Menon U, Manchanda R. Attitudes towards Risk Reducing Early Salpingectomy with Delayed Oophorectomy for Ovarian Cancer Prevention: a Cohort Study. BJOG 2020; https://doi.org/10.1111/1471-0528.16424 PMID 32803845

Keywords: Acceptability,BRCA, ovarian cancer, risk-reducingearly salpingectomy with delayed oophorectomy
95
Kramer P, Talhouk A, Brett MA, Chiu D, Cairns E, Scheunhage D, Hammond R, Farnell D, Nazeran T, Grube M, Xia Z, Senz J, Leung S, Feil L, Pasternak J, Dixon K, Hartkopf A, Kramer B, Brucker S, Heitz F, du Bois A, Harter P, Kommoss F, Sinn HP, Heublein S, Kommoss F, Vollert HW, Manchanda R, de Kroon C, Nijman H, de Bruyn M, Thompson E, Bashashati A, McAlpine J, Singh N, Tinker A, Staebler A, Bosse T, Kommoss S, Kobel M, Anglesio M. Translating endometrial molecular risk stratification to endometrioid ovarian carcinoma: a novel application of precision medicine. Clinical Cancer Research 2020; 26:5400–10. PMID 32737030 https://clincancerres.aacrjournals.org/content/early/2020/09/04/1078-0432.CCR-20-1268
Keywords: Molecular risk classification, endometrial cancer, prognosis
96
Manchanda R, Sun L, Patel S, Evans O, Wilschut J, Lopes ACDF, Gaba F, Brentnall A, Duffy S, Cui B, de Soarez PC, Husain Z, Hopper J, Sadique Z, Mukopadhyay A, Yang L, Berkhof J, Legood R. Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. Cancers 2020; 12(7):1929. https://doi.org/10.3390/cancers12071929 PMID: 32708835, PMCID: PMC7409094.

Keywords: BRCA; population testing; cost-effectiveness; ovarian cancer; breast cancer; cancer prevention
97
Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, Kalsi J, Dawnay A, Perez IM, Manchanda R, Lu KH, Yang WL, Timms JF, Parmar M, Skates S, Bast RC, Jacobs I, Zaikin A, Menon U. Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening. Cancers 2020. https://doi.org/10.3390/cancers12071931

Keywords: ovarian cancer; CA125; HE4; UKCTOCS; MMT; screening; postmenopausal women
98
Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R. Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. Cancers 2020; 12(5), 1241. doi:10.3390/cancers12051241 PMID: 32429029, PMCID: PMC7281662

Keywords: population genetic testing; ovarian cancer risk; risk stratification; BRCA1; BRCA2; RAD51C; RAD51D; BRIP1; SNP; risk modelling
99
Evans O, Manchanda R. Population-based Genetic Testing for Precision Prevention. Ca Prev Res 2020; DOI: 10.1158/1940-6207.CAPR-20-0002

Keywords: Population based testing, precision prevention, commentary
100
Evans O, Gaba F, Manchanda R. Population-based Genetic Testing for Women’s Cancer Prevention. Best Practice & Research Clinical Obstetrics & Gynaecology 2020; https://doi.org/10.1016/j.bpobgyn.2020.02.007

Keywords: Population based genetic testing, BRCA, ovarian, breast, Lynch Syndrome, Cancer
101

Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E. Population Screening for Inherited Predisposition to Breast and Ovarian Cancer. Annu Rev Genom Hum Genet. 2020; 21:13.1–13.40. https://doi.org/10.1146/annurev-genom-083118-015253 PMID 32315550

Keywords: BRCA1, BRCA2, Ashkenazi Jews, population screening, disease prevention, breast cancer
102
Gaba F, Manchanda R. Systematic Review of Acceptability, Cardiovascular, Neurological, Bone Health, and HRT Outcomes following Risk Reducing Surgery in BRCA carriers. Best Practice & Research Clinical Obstetrics & Gynaecology 2020; https://doi.org/10.1016/j.bpobgyn.2020.01.006

Keywords: RRSO, targeted surgical prevention, RRESDO, Ovarian cancer, acceptability, BRCA
103
Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, dos-Santos-Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol 2019; doi:10.1001/jamaoncol.2019.3323 (PMID: 31580391, PMCID: PMC6777250)

Keywords: Breast cancer, genetic testing, cost-effectiveness, unselected, BRCA
104
Gallagher A, Waller J, Manchanda R, Jacobs I, Sanderson S. Women’s intentions to engage in risk-reducing behaviours after receiving personal ovarian cancer risk information: an experimental survey study. Cancers. 2020 Nov 27;12(12):3543. PMID: 33260928

Keywords: attitudes; genomics; questionnaires; risk stratification
105
Manchanda R, Burnell M, Gaba F, Wardle J, Desai R, Gessler S, Side L, Sanderson S, Loggenberg K, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Legood R, Beller U, Tomlinson I, Menon U, and Jacobs I. Randomised trial of population based BRCA testing in Ashkenazi Jews: Long term outcomes. BJOG 2020; 127 (3): 364-375 https://doi.org/10.1111/1471-0528.15905. PMID: 31507061

Keywords: BRCA1; BRCA2; Ashkenazi Jews; genetic testing; population testing; psychological; quality-of-life.
106
Ryan N, Wall J, Crosbie EJ, Arends MJ, Bosse T, Arif S, Asma F, Frayling I, Ganesan R, Hock YL, McMahon R, Manchanda R, McCluggage GW, Mukonoweshuro P, van Schalkwyk G, Smith JH, Tanchel B, Evans DG, Gilks BC, Singh N. Lynch Syndrome Screening in Gynaecological Cancers: Results of an International Survey with Recommendations for Uniform Reporting Terminology for Mismatch Repair Immunohistochemistry Results. Histopathology 2019; 75: 813–824 doi:10.1111/his.13925 PMID 31310679

Keywords: Lynch syndrome; The Cancer Genome Atlas; consent; endometrial carcinoma; immunohistochemistry; mismatch repair; screening; terminology.
107

Cohen PA, Powell A, Bohm S, Gilks BC, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, Focchi GRdA, Ganesan R, Glasspool RM, Howitt BE, Kim H; Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage GW, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend, Yunokawa M, Zannoni GF, Singh N. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data. Gynecol Oncol 2019; 154(2):441-448. doi:10.1016/j.ygyno.2019.04.679 PMID 31118141

Keywords: Neoadjuvant chemotherapy, Chemotherapy response score, Prognosis, High-grade serous tubo-ovarian cancer
108
Manchanda R, Gaba F. A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm. BJOG 2019; 126: 686–689. https://doi.org/10.1111/1471-0528.15657 PMID:30770625

Keywords: genetic testing; population testing; ovarian cancer, breast cancer, BRCA, risk-reduction
109
Crosbie EJ, Ryan NAJ, Arends MA, Bosse T, Burn J, Cornes JM, Crawford R, Eccles D, Frayling IM, Ghaem-Maghami S, Hampel H, Kauff ND, Kitchener HC, Kitson SJ, Manchanda R, McMahon RFT, Monahan KJ, Menon U, Moller P, Moeslein G, Rosenthal A, Sasieni P, Seif MW, Singh N, Skarrott P, Snowsill TM, Steele R, Tischkowitz M, Manchester International Consensus Group, Evans DG. The Manchester International Consensus Group Recommendations for the Management of Gynecological Cancers in Lynch Syndrome. Genetics in Medicine 2019; https://doi.org/10.1038/s41436-019-0489-y PMID 30918358

Keywords: Lynch syndrome; endometrial cancer; guidance; screening; surveillance
110
Manchanda R, Burnell M, Gaba F, Sanderson S, Loggenberg K, Gessler S, Wardle J, Side L, Desai R, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Tomlinson I, Beller U, Menon U, and Jacobs I. Attitude towards and Factors affecting uptake of Population based BRCA testing in the Ashkenazi Jewish population: a cohort study. BJOG 2019; 126: 784–794. doi:10.1111/1471-0528.15654 PMID: 30767407

Keywords: BRCA; Ashkenazi Jews; attitude; genetic testing; intention; interest; population-based; uptake.
111
Gaba F, Piek J, Menon U, Manchanda R. Risk reducing early salpingectomy and delayed oophorectomy as a two staged alternative for primary prevention of ovarian cancer in increased risk women: a commentary. BJOG 2019; DOI: 10.1111/1471-0528.15651 PMID 30735593

Keywords: Ovarian cancer; risk-reduction, salpingo-oophorectomy, early salpingectomy; delayed oophorectomy; BRCA;
112

Koutoukidis DA, Beeken RJ, Manchanda R, Burnell M, Ziauddeen N, Michalopoulou M, Knobf MT, Lanceley A. Diet, physical activity, and health-related outcomes of endometrial cancer survivors in a behavioural lifestyle programme: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomised controlled pilot trial. Int J Gynecol Cancer 2018; DOI: 10.1136/ijgc-2018-000039 PMID 26965165

Keywords: Endometrial cancer, survivorship, behaviour change, healthy eating, physical activity
113
Manchanda R, Gaba F. Population Based Testing for Primary Prevention: a Systematic Review. Cancers 2018, 10, 424; doi:10.3390/cancers10110424. PMID: 30400647

Keywords: BRCA; Jewish; cancer prevention; general population; genetic testing; population testing; primary prevention.

114
Puntambekar S, Manchanda R. Surgical pelvic anatomy in gynecologic oncology. FIGO Cancer Report 2018. Int J Gynecol Obstet 2018; 143 (Suppl. 2): 86–92. DOI:10.1002/ijgo.12616 PMID 30306582

Keywords: FIGO Cancer Report; Gynecologic oncology; Hypogastric nerve; Laparoscopy; Pelvic anatomy; Predictive anatomy.
115
Vazquez MA, Marino IP, Blyuss O, Ryan A, Gentry-Maharaj A, Kalsi J, Manchanda R, Jacobs I, Menon U, Zaikin A. A Quantitative Performance Study of Two Automatic Methods for the Diagnosis of Ovarian Cancer. Biomedical Signal Processing and Control 2018; 46:86–93. https://doi.org/10.1016/j.bspc.2018.07.001 PMID 30245736

Keywords: Bayesian estimation; Biomarkers; Change-point detection; Deep learning; Gibbs sampling; Markov chain; Monte Carlo; Ovarian cancer; Recurrent neural networks.

116
Blyuss O, Burnell M, Ryan A, Gentry-Maharaj A, Marino IP, Kalsi J, Manchanda R, Timms JF, Parmar M, Skates SJ, Jacobs I, Zaikin A, Menon U. Comparison of longitudinal CA125 algorithms as a first line screen for ovarian cancer in the general population. Clin Cancer Res 2018; DOI:10.1158/1078-0432.CCR-18-0208 PMID 30084833

Keywords: UKCTOCS, CA125, Ovarian cancer, screening, longitudinal algorithms, PEB, MMT, ROCA
117
Chuang L, Bere J, Randall T, McCormack M, Schmeler K, Manchanda R, Rebbeck T, Jeng CJ, Pyle D, Quinn M, Trimble E, Naik R, Lai CH, Ochiai K, Denny L, Bhatla N. International Collaborations in Gynecologic Oncology Education and Research in Low- and Middle- Income Countries: Current Status, Barriers and Opportunities. Gynecologic Oncology Reports; 2018; 25: 65-69 https://doi.org/10.1016/j.gore.2018.05.005 PMID: 29928684 PMCID: PMC6008286

Keywords: Low- and middle-income countries, Education, Research, Opportunities, Scholarships
118
Yang X, Leslie G, Gentry-Maharaj A, Ryan A, Intermaggio M, Lee A, Kalsi JK, Tyrer J, Gaba F, Manchanda R, Pharoah PDP, Gayther SA, Ramus SJ, Jacobs I, Menon U, Antoniou AC. Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. J Med Genet; 2018 dx.doi.org/10.1136/jmedgenet-2018-105313 PMID: 29730597

Keywords: evaluation; ovarian cancer; polygenic risk scores; prospective cohort study; risk prediction.
119
Manchanda R, Blyuss O, Gaba F, Gordeev VS, Jacobs C, Burnell M, Gan M, Taylor R, Turnbull C, Legood R, Zaikin A, Antoniou AC, Menon U, Jacobs I. Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. J Med Genet; 2018; doi:10.1136/jmedgenet-2017-105195. PMID: 29622727

Keywords: Brca; detection rate; genetic testing; prediction; time to detection.
120
Manchanda R, Patel S, Gordeev V, Antoniou AC, Smith S, Lee A, Hopper JL, MacInnis RJ, Turnbull C, Ramus SJ, Gayther SA, Pharoah PDP, Menon U, Jacobs I, Legood R. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation-testing in unselected general-population women. J Natl Cancer Inst 2018; 110(7): djx265. doi:10.1093/jnci/djx265 PMID:29361001

Keywords: Mutation; cancer; cost effectiveness; BRCA; PALB2; life expectancy; quality-adjusted life years; mastectomy; breast cancer; genetic testing
121
Patel S, Legood R, Evans DG, Turnbull C, Antoniou AC, Menon U, Jacobs I, Manchanda R. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. Am J Obstet Gynecol, 2018; DOI: 10.1016/j.ajog.2017.12.221, PMID: 29288066

Keywords: BRCA; Sephardi Jewish; cost effectiveness; population testing.
122
Manchanda R, Menon U. Setting the threshold for surgical prevention in women at increased risk of ovarian cancer. Int J Gynecol Cancer, 2018; 28(1): DOI: 10.1097/IGC.0000000000001147 PMID:29252925

Keywords: Ovarian cancer; risk-reduction; salpingo-oophorectomy; threshold; cancer risk;
123
Meisel SF, Freeman M, Waller J, Fraser L, Gessler S, Jacobs I, Kalsi J, Manchanda R, Rahman B, Side L, Wardle J, Lanceley A, Sanderson SC. Impact of a decision aid about stratified ovarian cancer risk-management on women’s knowledge and intentions: a randomised online experimental survey study. BMC Public Health 2017; DOI:10.1186/s12889-017-4889-0 PMID 29145813

Keywords: Ovarian cancer; personalised prediction; decision aid; information; risk-reduction; experimental survey;
124
Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans G, Hopper J, MacInnis RJ, Menon U, Jacobs I, Legood R. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. Am J Obstet Gynecol, 2017; doi.org/10.1016/j.ajog.2017.06.038 PMID: 28690137

Keywords: Ashkenazi Jewish; BRCA; ancestry; cost-effectiveness; population testing.
125
Koutoukidis DA, Beeken RJ, Manchanda R, Michalopoulou M, Burnell M, Knobf MT, Lanceley A. Recruitment, adherence, and retention of endometrial cancer survivors in a behavioural lifestyle programme: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomised pilot trial. BMJ Open, 2017;7:e018015. doi:10.1136/bmjopen-2017-018015 PMID 28993394

Keywords: Endometrial cancer; behaviour change; healthy eating; intervention; physical activity; survivorship.

126
Gan C, Chenoy, R, Chandrasekaran D, Brockbank E, Hollingworth A, Vimplis S, Lawrence AC, Jeyarajah A, Oram D, Deo N, Saravanamuthu J, Lam SS, Faruqi A, Singh N, Manchanda R. Persistence of fimbrial tissue on the ovarian surface following salpingectomy. Am J Obstet Gynecol, 2017; doi.org/10.1016/j.ajog.2017.06.004 PMID 28610900

Keywords: high-grade serous carcinoma; ovarian cancer; ovarian surface; residual fimbrial tissue; salpingectomy.

127
Manchanda R, Legood R, Antoniou AC, Pearce L, Menon U. Changing the Risk Threshold for Surgical Prevention of Ovarian Cancer. BJOG: Int J Obstet Gy, 2017; doi: 10.1111/1471-0528.14763 PMID:28548227

Keywords: Ovarian cancer; risk-reduction; risk threshold; salpingo-oophorectomy; salpingectomy; hysterectomy; contraceptive pill; cost-effectiveness

128
Bansal JK, Goldrick IG, Manchanda R, Olaitan A. Rapid access gynecological oncology clinic outcomes in North London, UK. Clinical Audit, 2017:9 19–23. http://dx.doi.org/10.2147/CA.S127369

Keywords: Gynaecological oncology; rapid access; urgent referral; gynecology, general practice, 2-week wait, genital neoplasms, gynecological cancers

129
Rosenthal AN, Fraser L, Philpott S, Manchanda R, Burnell M, Badman P, Hadwin R, Rizzuto I, Benjamin E, Singh N, Evans DRG, Eccles DM, Ryan A, Liston R, Dawnay A, Ford J, Gunu RG, Mackay J, Skates SJ, Menon U, and Jacobs IJ. Evidence of stage-shift in women diagnosed with ovarian cancer during Phase 2 of the UK Familial Ovarian Cancer Screening Study (UKFOCSS). J Clin Oncol, Mar 2017 DOI: 10.1200/JCO.2016.69.9330 PMID:28240969

Keywords: Ovarian cancer; screening; ROCA; ultrasound;

130
Johnston C, Ng J, Manchanda R, Tsunoda AT, Chuang L. Variations in gynecologic oncology training in low (LIC) and middle income (MIC) countries (LMICs): common efforts and challenges. Gynaecol Oncol Rep, 2017; 20: 9–14. DOI: 10.1016/j.gore.2017.01.003 PMID: 28203627 PMCID: PMC5295505

Keywords: Gynecologic: Oncology; LMICs; Training.

131
Gan C, Bossart M, Piek J, Halaska M, Haidopoulos D, Zapardiel I, Grabowski JP, Kesic V, Kimmig R, Cibula D, Lambaudie E Verheijen R, Manchanda R. Robotic and advanced laparoscopic surgical training in European gynaecological oncology trainees. Int J Gynaecol Cancer, 2017; 27(2): 375-381. DOI: 10.1097/IGC.0000000000000879 PMID 28114237

Keywords: Gynaecological oncology; surgery; training; laparoscopic; robotic; European
132
Gaba F, Manchanda R. Genetic Testing for Gynaecological Cancer. Obstetrics, Gynaecology and Reproductive Medicine, 2017; 27(1): 29-31 http://dx.doi.org/10.1016/j.ogrm.2016.11.001

Keywords: BRCA; breast cancer; endometrial cancer; genetic testing; high risk; Lynch syndrome; ovarian cancer; risk prediction

133
Pennington M, Gentry-Maharaj A, Karpinskyj C, Miners A, Taylor J, Manchanda R, Iyer R, Griffin M, Ryan A, Jacobs IJ, Menon U, Legood R. Long-term secondary care costs of endometrial cancer: a prospective cohort study nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Plos One, 2016, DOI:10.1371/journal.pone.0165539 PMID: 27829038 PMCID: PMC5102347

Keywords: Endometrial cancer; care costs; cohort

134
Chuang LT, Randall TC, Denny L, Johnston CM, Schmeler KM, Covens AL, Cibula D, Bookman MA, Rawal S, DePetrillo D, Nam JH, Goodman A, Naik R, Manchanda R, Gaffney DK, Small W Jr, Creutzberg C, Rattray C, Kesic V, Paraja R, Eiken M, Belleson K, Coleman RL, Barakat RR, Trimble EL, Quinn M. Sister Society Meeting on Global Education Development and Collaboration: Meeting Report. Int J Gynecol Cancer. 2016 Jul;26(6):1186-8. doi:10.1097/IGC.0000000000000735. PMID 27327155

Keywords: Gynaecological oncology; training; low middle income countries; education programmes; global curriculum
135
Manchanda R, Legood R, Antoniou AC, Gordeev SV, Menon U. Specifying the risk threshold of premenopausal risk reducing salpingo-oophorectomy for ovarian cancer prevention: a cost-effectiveness analysis. J Med Genet 2016;53:591–599. doi:10.1136/jmedgenet-2016-103800. PMID:27354448

Keywords: Ovarian cancer; cost-effectiveness; risk reducing salpingo-oophorectomy; risk threshold; surgical prevention.


136
Manchanda R, Burnell M, Loggenberg K, Desai R, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Kumar A, Dorkins H, Wallis Y, Chapman C, Tomlinson I, Taylor R, Jacobs C, Legood R, Raikou M, McGuire A, Beller U, Menon U, and Jacobs I. Cluster randomised non-inferiority trial comparing DVD-based and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. J Med Genet, 2016, 53(7):472-80. doi:10.1136/jmedgenet-2015-103740. PMID: 26993268

Keywords: BRCA1, BRCA2; Cluster Randomised trial; Genetic screening/counselling; Population based testing; genetic testing.


137
Burnell M, Iyer R, Gentry-Maharaj A, Nordin A, Liston R, Manchanda R, Das N, Gornall R, Beardmore-Gray A, Hillaby K, Leeson S, Linder A, Lopes A, Meechan D, Mould T, Nevin J, Olaitan A, Rufford B, Shanbhag S, Thackeray A, Wood N, Reynolds K, Ryan A, Menon U. Benchmarking of surgical complications in gynaecological oncology: prospective multicentre study. BJOG, 2016; DOI: 10.1111/1471-0528.13994 PMID 27006076

Keywords: UKGOSOC; Benchmarking; centres; comparison; complications; gynaecological oncology; risk adjustment; surgery.

138
Burnell M, Iyer R, Gentry-Maharaj A, Nordin A, Liston R, Manchanda R, Das N, Gornall R, Beardmore-Gray A, Hillaby K, Leeson S, Linder A, Lopes A, Meechan D, Mould T, Nevin J, Olaitan A, Rufford B, Shanbhag S, Thackeray A, Wood N, Reynolds K, Ryan A, Menon U. Benchmarking of surgical complications in gynaecological oncology: prospective multicentre study. BJOG, 2016; DOI: 10.1111/1471-0528.13994 PMID 27006076

Keywords: UKGOSOC; Benchmarking; centres; comparison; complications; gynaecological oncology; risk adjustment; surgery.

139
Koutoukidis DA, Beeken RJ, Manchanda R, Burnell1 M, Knobf MT, Lanceley A. Diet and exercise in uterine cancer survivors (DEUS pilot) – piloting a healthy eating and physical activity program: study protocol for a randomized controlled trial. Trials, 2016: 17;130 DOI 10.1186/s13063-016-1260-1 PMID: 26965165 PMCID: PMC4785620

Keywords: Endometrial cancer; behaviour change; healthy eating; physical activity; survivorship.

140
Manchanda R, Menon U. Opportunistic Bilateral Salpingectomy (OBS) for prevention of ovarian cancer should be offered in the context of a clinical trial. BJOG, 2016 PMID 26810679

Keywords: Ovarian cancer, prevention, opportunistic salpingectomy, clinician opinion, survey

141
Manchanda R, Chandrasekaran D, Saridogan E, Burnell M, Crawford R, Brockbank E, Kalsi J, Jurkovic D, and Menon U. Should Opportunistic Bilateral Salpingectomy (OBS) for prevention of ovarian cancer be incorporated into routine care or offered in the context of a clinical trial? Int J Gynecol Cancer, 2016; 26(1): 31-32. PMID 26658362

Keywords: Ovarian cancer, prevention, opportunistic salpingectomy, clinician opinion, survey

142
Manchanda R, Jacobs I. Genetic screening for gynaecological cancer: where are we heading? Future Oncol, Dec 2015 http://www.ncbi.nlm.nih.gov/pubmed/26638726

Keywords: BRCA1; BRCA2; cancer genes; genetic screening; genetic testing; population screening; risk prediction; risk stratification.

143
Manchanda R, Legood R, Pearce L, Menon U. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. Gynecol Oncol, 2015, 139(3):487-94. http://dx.doi.org/10.1016/j.ygyno.2015.10.001 PMID:26436478

Keywords: Cancer prevention; Ovarian neoplasm; Risk reducing salpingo-oophorectomy; QALY, Risk prediction; Cost effectiveness

144
*Dilley J, *Manchanda R, Johnson M, Rosenthal AN, Gessler S, Menon U. Importance of serial CA125 measurements over an absolute cut-off value for detection of asymptomatic ovarian cancer in high-risk patients. Int J Gynecol Obstet, 2015 //dx.doi.org/10.1016/j.ijgo.2015.09.013 PMID: 26868067

Keywords: CA-125; screening; ovarian cancer; cancer prevention; ROCA

145
Chandrasekharan D, Menon U, Evans G, Crawford R, Saridogan E, Jacobs C, Tischkowitz M, Brockbank E, Kalsi J, Jurkovic D, Manchanda R. Risk Reducing Salpingectomy and Delayed Oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. Fam Cancer July 2015 DOI 10.1007/s10689-015-9823-y PMID: 26178205

Keywords: BRCA; Delayed oophorectomy; High-risk; Ovarian cancer; RRSDO; Risk reducing salpingectomy.

146
Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, Manchanda R, Easton D, Jacobs I, Pharoah P, Antoniou A. A Risk Prediction Algorithm for Ovarian Cancer Incorporating BRCA1, BRCA2, Common Alleles and Other Familial Effects. J Med Genet 2015; 52(7):465-75. doi:10.1136/jmedgenet-2015-103077 PMID: 26868067

Keywords: Genetic epidemiology; Genetic screening/counselling; Genome-wide; Ovarian Cancer; Risk prediction.

147
Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, and Jacobs I. Cost effectiveness of population screening for BRCA mutations in Ashkenazi-Jewish women compared to family-history based testing. J Natl Cancer Inst 2015; 107(1): doi:10.1093/jnci/dju380 PMID: 25435542 PMCID: PMC4301704

Keywords: BRCA; cost-effectiveness; population testing; Ashkenazi Jewish

148
Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, R, Jacobs C, Tomlinson I, McGuire A, Beller U, Menon U, and Jacobs I. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomised controlled trial. J Natl Cancer Inst 2015; 107(1): doi:10.1093/jnci/dju379 PMID:25435541, PMCID:PMC4301703

Keywords: Population testing; BRCA; Ashkenazi Jewish; Randomised control trial; quality-of-life

149
Iyer R, Gentry-Maharaj A, Nordin A, Burnell M, Liston R, Manchanda R, Das N, Desai R, Gornall R, Beardmore-Gray A, Nevin J, Hillaby K, Leeson S, Linder A, Lopes A, Meechan D, Mould T, Varkey S, Olaitan A, Rufford B, Ryan A, Shanbhag S, Thackeray A, Wood N, Reynolds K, and Menon U. Predictors of complications in gynaecological oncological surgery. Br J Cancer 2014 doi: 10.1038/bjc.2014.630 PMID: 25535730

Keywords: UKGOSOC; complications; surgery; gynaecological oncology; predictors; intra-op; post-op

150
Piek J, Bossart M, Boor K, Halaska M, Haidopoulos D, Zapardiel I, Grabowski J, Kesic V, Cibula D, Colombo N, Verheijen R, Manchanda R. The work place educational climate in gynecological oncology fellowships across Europe: the impact of accreditation. Int J Gynecol Cancer 2015; 25(1): 180-190. DOI: 10.1097/IGC.0000000000000323

Keywords: Educational climate; D-RECT; Gynecological oncology training; accreditation; ENYGO

151
Manchanda R, Hallaska MJ, Piek J et al. The need for more workshops in laparoscopic surgery and surgical anatomy for European gynaecological oncology trainees: a survey by ENYGO. Int J Gynecol Cancer 2013; 23(6): 1126-31. PMID: 23792606

Keywords: ENYGO; Gynaecologic oncology; training; laparoscopic surgery; surgical anatomy; European

152
Kalsi J, Manchanda R, Menon U. Screening for gynaecological cancers. Expert Rev Obstet Gynecol. 2013; 8(2): 143–160

Keywords: Cervical; ovarian; endometrial; gynaecological cancer; screening

153
Manchanda R, Godfrey M, Wong-Taylor LA, Halaska MJ, Burnell M, Grabowski JP, Gultekin M, Haidopoulos D, Zapardiel I, Vranes B, Kesic V, Zola P, Colombo N, Verheijen R, Bossart M, Piek J. The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO). Ann Oncol, 2013; 24(4), 944-52 PMID: 23172637

Keywords: Accredited programme; ENYGO; ESGO; Europe; gynaecological oncology; training

154
Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans G, EcclesD, Skates SJ, MacKay J, Menon U, Jacobs IJ on behalf of the UK FOCSS collaborators. Results of annual screening in Phase I of the United Kingdom familial ovarian cancer screening study highlight need for strict adherence to screening schedule. J Clin Oncol 2013; 31(1):49-57. PMID:23213100

Keywords: UKFOCSS, ovarian cancer; screening; BRCA; CA-125; ultrasound; screening interval

155
Brantnerova R, Manchanda R, Colombo N. The European Society of Gynaecological Oncology: Update on Objectives and Educational and Research Activities. Am Soc Clin Oncol Educ Book 2012; 32: 335-338 PMID: 24451759

Keywords: ESGO; ENGO; ENGOT; ENTRIGO; Educational activity; Research activity;

156
Manchanda R, Saridogan E, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Side L, Gessler S, Jacobs I, Menon U. Annual Outpatient Hysteroscopy and Endometrial Sampling (OHES) in HNPCC/ Lynch Syndrome (LS). Archives Gynecol Obstet, 2012; 286(6): 1555-62 PMID: 22865035

Keywords: Lynch syndrome; endometrial screening; outpatient hysteroscopy; endometrial sampling; OHES

157
Fourkala E, Gentry-Maharaj A, Burnell M, Ryan A, Manchanda R, Dawnay A, Jacobs I, Widschwendter M, Menon U. Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Br J Cancer. 2012; 106: 1910-6. PMID: 22596242

Keywords: breast cancer, cancer registry, self-reporting, UKCTOCS

158
Manchanda R, Silvanto A, Abdelraheim A, Burnell M, Johnson M, Saridogan E, Rosenthal AN, Brunell C, Aslam N, Vashisht A, Pandis G, Jacobs I, Menon U, Benjamin E. Surgical diathermy induced tubal injury may affect detection of occult tubal lesions in high-risk women undergoing risk reducing salpingo-oophorectomy (RRSO). Int J Gynecol Cancer. 2012; 22: 881-8. doi:10.1097/IGC.0b013e31824b4093 PMID:22572844

Keywords: Risk-reducing salpingo-oophorectomy, Diathermy, Electrosurgery, Thermal injury, Tubal injury, Occult pathology, Fallopian tube, BRCA, Fimbrial

159
Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Rosenthal AN, Benjamin E, Brunell C, Saridogan E, Oram D, Side L, Gessler S, Jacobs I, Menon U. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy (RRSO) in women at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG 2012; 119: 527-36 PMID: 22260402

Keywords: BRCA, competing risk, ovarian cancer, risk-reducing salpingo-oophorectomy, tubal cancer, unknown mutation status

160
Manchanda R, Drapkin R, Jacobs I, Menon U. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecol Oncol 2012 Feb; 124(2):185-91. PMID: 22019526

Keywords: Peritoneal cytology; salpingo-oophorectomy; RRSO; risk-reducing; BRCA;

161
Vaes E, Manchanda R, Autier P, Nir R, Nir D, Bleiberg H, Robert A and Menon U. Differential diagnosis of adnexal masses: A sequential use of the Risk of Malignancy Index and a novel computer aided diagnostic tool. Ultrasound Obstet Gynecol 2012; 39: 91–98. PMID: 21695741

Keywords: differential diagnosis; HistoScanning; ovarian cancer; RMI; sequential strategy; ultrasound

162
Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Jurgen P, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Dahl Steffensen K, Gristsenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Dimitrios T, Peiretti M, Dunenova G, Macuks R, Hetland T, Michelsen TM, Martins F, Achimas-Cadariu P, Ulrikh E, Uharcek P, Malic S, Ognjenovic D, Zapardiel I, Johann S, Sukhin VS, Manchanda R. Gynaecologic Oncology Training Systems in Europe: A report from the European Network of Young Gynaecological Oncologists (ENYGO). Int J Gynecol Cancer 2011 Nov; 21(8):1500-6. PMID: 33361458

Keywords: Gynaecological oncology training; ESGO; ENYGO; Europe; survey;

163
Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Brunell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U. ‘Outcome of risk reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status’ BJOG 2011;
118: 814-24 PMID: 21392246

Keywords: BRCA, occult cancer, ovarian cancer, risk-reducing salpingo-oophorectomy, tubal cancer, unknown mutation status

164
Vaes E, Manchanda R, Nir R, Nir D, Bleiberg H, Autier P, Menon U, Robert A. Mathematical models to discriminate between benign and malignant adnexal masses: potential diagnostic improvement using Ovarian HistoScanning. Int J Gynecol Cancer 2011; 21(1): 35-43. PMID: 21330829

Keywords: Differential diagnosis, Ovarian cancer, Multivariate mathematical models, HistoScanning, Ultrasound

165
Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif M, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J , Williamson K, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Skates S, Fallowfield L, Parmar M, Campbell S, Menon U. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol; 2011 12(1):38-48 PMID: 21147030

Keywords: TVUS; ultrasound; endometrial cancer; UKCTOCS; screening

166
Pichert G, Jacobs C, Jacobs I, Menon U, Manchanda R, Johnson M, Hamed H, Firth C, Evison M, Tutt A, de Silva L, Langman C, Izatt L. Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Fam Cancer 2010 Sep;9(3):313-9 PMID: 20300867

Keywords: BRCA1, BRCA2, Breast cancer, Cancer risk management, Ovarian cancer

167
Manchanda R, Rosenthal A Burnell M, Fraser L, Mackay J, Skates S. Change in stage distribution observed with annual screening for ovarian cancer in BRCA carriers. J. Med. Genet. 2009; 46: 423-424 PMID: 19487541

Keywords: Ovarian cancer, annual screening, stage-shift; mortality

GCaPPS: Genetic Cancer Prediction through Population Screening
(2008-2019)

Following pre-test counselling and informed consent, 1034 Ashkenazi Jewish men and women were randomised to either population based or clinical criteria (family history) based genetic testing for BRCA founder mutations. Participants were followed up for three years after the test result. The study showed that compared to family-history based testing, population-based BRCA founder mutation testing doesn’t harm psychological health (anxiety, depression, health anxiety, distress, uncertainty)  or quality-of-life and identifies 150% additional BRCA carriers. Overall anxiety decreased with time. Long term follow up data shows a reduction in anxiety with population testing compared to family-history or clinical criteria based testing. We found BRCA testing in the Jewish population is acceptable, feasible, and can be undertaken in a community setting. It had high acceptability and was associated with 88% uptake and high satisfaction rates of ~95%. In a non-inferiority cluster-randomised trial we found that DVD-assisted pre-test counselling for population BRCA-testing is an effective, acceptable, non-inferior, time-saving and cost-efficient alternative to traditional genetic-counselling.

Our cost-effectiveness analysis shows, a population-based BRCA testing approach in the Ashkenazi Jewish population, reduces breast and ovarian cancer incidence, leading to up to an additional 33 days gain in life-expectancy and is extremely cost-effective (cost saving) with a discounted incremental cost-effectiveness ratio (ICER) = -£2960/quality adjusted life year (QALY). Probabilistic sensitivity analysis shows this remains cost-effective for 95% simulations at the £20,000/QALY NICE threshold. Our modelling suggests this could lead to 276 fewer ovarian and 508 fewer breast cancer cases in the UK. Overall, reduction in treatment costs could lead to a discounted cost savings of £3.7 million for the NHS.

Cost-effectiveness Population BRCA testing in Canada(2022-2024)
Evaluation of cost-effectiveness of population based BRCA testing in Canada. This project is being undertaken in collaboration with the team in British Columbia led by Prof Kwon and Prof Dawson.
PROMISE Feasibility Study
(2016-2019)
This pilot study into the impact of population based genetic testing for ovarian/breast cancer gene mutations recruited 103 women from the general population. It found that population-based testing is feasible and acceptable, has high satisfaction, reduces cancer worry/risk perception, and does not negatively impact psychological health/quality of life.
Cost-effectiveness analysis of multigene testing at breast cancer diagnosis

This study investigated whether offering unselected genetic testing of a panel of BRCA1/BRCA2/PALB2 genes to everyone diagnosed with breast cancer was cost-effective compared to the current model of BRCA1/BRCA2 testing based on a patient’s family history/clinical criteria. This study found that unselected panel gene testing for everyone at breast cancer diagnosis was highly cost-effective compared to the current model of testing for UK and US health systems, and could save 2101 cases of ovarian and breast cancer in the UK, and 2406 in the US per year.

Value based genetic technology for breast cancer in China. (2020-2023)

Evaluating cost-effectiveness of population based panel genetic testing for ovarian/breast cancer gene mutations in the general population (2016-2019)
This study evaluated the cost-utility of unselected genetic testing (for BRCA1/BRCA2/PALB2) for all patients diagnosed with breast cancer in the UK and USA, compared to the traditional family history/clinical criteria approach. Unselected testing was cost-effective in both systems, and could prevent 2101 cases of breast/ovarian cancer in the UK, and 9733 cases in the USA.
Cost-effectiveness analysis of multigene testing at breast cancer diagnosis

This study investigated whether offering unselected genetic testing of a panel of BRCA1/BRCA2/PALB2 genes to everyone diagnosed with breast cancer was cost-effective compared to the current model of BRCA1/BRCA2 testing based on a patient’s family history/clinical criteria. This study found that unselected panel gene testing for everyone at breast cancer diagnosis was highly cost-effective compared to the current model of testing for UK and US health systems, and could save 2101 cases of ovarian and breast cancer in the UK, and 2406 in the US per year.

Value based genetic technology for breast cancer in China. (2020-2023)

RRESDO Study

A multicentre UK cohort questionnaire study to determine risk-reducing early salpingectomy and delayed oophorectomy (RRESDO) acceptability and effect of surgical prevention on menopausal sequelae/satisfaction/regret in women at increased ovarian cancer (OC) risk.

We found that RRESDO has high acceptability among premenopausal women at increased ovarian cancer risk, particularly those concerned about sexual dysfunction.

Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems

This study evaluated the cost-effectiveness of population-based BRCA testing in general population women across different countries/health systems. Our findings are split across high-income (HIC), upper-middle income (UMIC) and low-middle income countries (LMIC). Our findings suggest that population-based BRCA testing for countries evaluated is extremely cost-effective across high (US/UK/Netherlands) and upper/middle income countries’ health systems (China/Brazil), is cost-saving for high-income health systems from a societal perspective, and can prevent tens of thousands more breast or ovarian cancer cases.

Defining the ‘risk thresholds’ for risk reducing salpingo-oophorectomy (RRSO) for ovarian cancer prevention

We for the first time defined the precise ovarian cancer risk thresholds at which risk reducing salpingo oophorectomy (preventive surgery) should be undertaken for ovarian cancer prevention in both pre- and post-menopausal women. 

Our findings show this is cost-effective in intermediate risk women too, saving 7-10 years of a woman’s life. This has significant implications for a number of women who currently can’t access risk reducing surgery. It also provides clinical utility for genetic testing of intermediate risk ovarian cancer genes. This has led to change in guidelines/practice for surgical prevention of ovarian cancer.

Previous projects supported by our team

Value based genetic technology for breast cancer in China (2020-2023)

Investigating BRCAness in epithelial ovarian cancer (EOC) in India to develop stratified surgical and chemotherapy options (2017-2020)

Correlation of p53 IHC expression with TP53 mutation status in Endometrial Carcinoma (Co-investigator) (2017-2019)

UK FOCSS – UK Familial Ovarian Cancer Screening Study

UKCTOCS – UK Collaborative Trial of Ovarian Cancer Screening

ALDO – Avoiding late diagnosis of ovarian cancer

Shape Up following cancer treatment

SOCQER2

Use of Plasmajet in ultra-radical surgery for advanced Ovarian Cancer (2015-2019)

SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management programme (2020-2021)

SHAPE

STATEC

MAPPING

ROCkeTS

SCCAN

GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V)

For more details on these support projects, click here!

PROTECTOR: Preventing Ovarian Cancer Through early Excision of Tubes & late Ovarian Removal

PROTECTOR is a research study for women who are at an increased risk of developing ovarian cancer, due a strong family history of cancer, or an alteration in genes (such as BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, or PALB2). This study assesses the impact of surgery to remove the fallopian tubes and ovaries to prevent ovarian cancer. 

Participants can choose whether to have no surgery, the usual operation to remove both tubes and ovaries, or a new 2-step approach of removing the fallopian tubes first followed by a second operation to remove the ovaries later. 

The study assesses the impact of these surgeries on sexual function, hormone levels, quality of life and overall satisfaction. 41 sites across the UK are recruiting. PROTECTOR is funded by Barts Charity & Rosetrees Trust.

PROTECTOR Phase 1 has completed recruitment, and we are looking to open for Phase 2 in January 2025. 

For more information please visit: http://www.protector.org.uk/
DETECT-2: Direct to Patient testing at Cancer diagnosis for Precision Prevention-2

DETECT-2 is a study investigating if genetic testing can be offered to people in their own home.

In this study, participants who have been diagnosed with ovarian, womb, or bowel cancer are randomly assigned to be offered either conventional genetic testing by their cancer team or genetic testing at home. This new model is called “direct-to-patient” testing and includes offering genetic testing information on an interactive app or website, and offering genetic testing by a home saliva kit posted to participants.

DETECT-2 will assess if direct-to-patient genetic testing impacts participants’ willingness to accept genetic testing, or has an impact on their quality-of-life, satisfaction, or mental wellbeing. It will also assess if direct-to-patient testing is cost-effective.

DETECT-2 is supported by GSK and the North East London Cancer Alliance

For more information please visit: https://www.detect-2.co.uk/
PRESCORES: Prevention of endometrial cancer: Utility scores of risk-reducing strategies
PRESCORES is a research study looking into the quality of life of women after an operation to prevent womb (endometrial) cancer. This operation is known as risk-reducing hysterectomy. We will use this to understand whether more people at risk of this cancer could benefit from this operation.
For more information please visit: PRESCORES – Wolfson Institute of Population Health (qmul.ac.uk)
PROTECT-C: Population based germline testing for early detection and prevention of cancer

PROTECT-C is offering genetic testing to women (women, trans men and non-binary people with female reproductive organs) to see if they have an increased risk of breast, ovary, bowel and/or womb cancer. This is regardless of whether they or their families have had cancer.

Specially trained counsellors are available through a helpline (telephone, virtual, email). If a participant decides to proceed with genetic testing, they will be sent a saliva kit for genetic testing at home (a “direct-to-patient” approach).

PROTECT-C aims to find out how many women decide to have genetic testing, their experience, and how this affects their quality of life, satisfaction and mental well-being. 

PROTECT-C will assess the number of people identified to be at increased risk, and how many of them take up screening and prevention options. The study will also assess whether it is cost-effective for the NHS to offer genetic testing to all women in the population.

PROTECT-C is funded by a £3.89 million research grant from Yorkshire Cancer Research, and is aiming to launch in 2025.

For more information please visit: https://protect-c.co.uk

JHCR: The Jewish Hereditary Cancer Review

This project aims to review the status of BRCA awareness, community support and BRCA testing provision, experience and satisfaction in the ‘at-increased-risk’ Jewish community in the UK.

The review will focus on hereditary cancers associated with BRCA1 and BRCA2 gene mutations. It will concentrate on the provision of BRCA information and testing in the UK and also look at BRCA-related activities in Jewish communities internationally.

Delivery of the research will be carried out by researchers based at Queen Mary University of London in partnership with the JHCR project director, and under the guidance of expert advisors.

Research outcomes will help identify priority needs and recommendations to improve BRCA awareness in, and access to responsible BRCA testing for, the UK Jewish community.

Findings will be published in a community report and scientific papers – raising awareness and promoting positive action to improve hereditary cancer management and prevention in the UK Jewish community.

For more information please visit: https://wpprevention.org/jhcr-the-jewish-hereditary-cancer-review/ 
OVACATCH: Ovarian Cancer Targeted Early Detection for Faster Diagnosis at a Curable Stage

Ovarian cancer is typically diagnosed at a late stage which is associated with a worse prognosis. There are also no effective screening tests available for ovarian cancer. 

OVACATCH aims to improve earlier diagnosis of ovarian cancer or identify cancers that current investigations may miss, by using longitudinal multiple biomarker algorithms derived from serum blood tests.

These will be validated using prospectively collected longitudinal serum samples held in biobanks from women with cancer diagnoses and healthy controls. A prospective cohort screening trial will then be conducted to evaluate these multi-marker algorithms compared to current methods of ovarian cancer surveillance using ROCA (Risk of Ovarian Cancer Algorithm). 

OVACATCH will evaluate false positive rate, feasibility, compliances, satisfaction and anxiety with screening. This will provide the initial data needed to design a large multicentre screening trial for ovarian cancer, moving the needle forward towards developing an effective screening strategy for ovarian cancer.

SECRETS: Serous endometrial cancer risk and role of risk-reducing hysterectomy in BRCA carriers

The current literature around risk of serous endometrial cancer in BRCA pathogenic variant (PV) carriers is equivocal. There have been few studies that have stratified the risk in serous endometrial cancers and none focusing specifically on this histopathological subtype of endometrial cancer.

 There have been no case-control studies to address this issue and the cohort studies demonstrating increased risk report large confidence intervals, while some others found no increase in risk. The true prevalence of BRCA1/BRCA2 PVs in prospective unselected UK serous EC patients is unknown. There remains continued uncertainty around whether BRCA1 PV carriers should undergo preventive hysterectomy (or not).

This study will address knowledge gaps such as the risk of serous endometrial cancer in patients with BRCA1/BRCA2 PVs, if hysterectomy would be cost-effective in the UK for BRCA1 and BRCA2 PV carriers, and if hysterectomy is acceptable alongside risk-reducing salpingo-oophorectomy for these carriers. 

UKCOGS: UK COVID and Gynaecological Cancer Study 

UKCOGS is a national study into the changes in diagnosis and treatment of gynaecological oncology patients that occurred in response to COVID-19. It aims to understand the decisions made by multi-disciplinary teams working in gynaecological oncology hospitals, the changes that occurred in these hospitals, and the impact of these changes on the health and survival of cancer patients.

The study is endorsed and supported by the British Gynaecological Cancer Society, Royal College of Obstetricians and Gynaecologists, NCRI Gynaecological Cancer Clinical Studies Group, British Association of Gynaecological Pathologists, and charities including Ovacome, The Eve Appeal, Target Ovarian Cancer, Ovarian Cancer Action, Jo’s Cervical Cancer trust and GO Girls.

For more information please visit: https://www.bgcs.org.uk/professionals/covid19-resources/research-studies/

SIGNPOST: Systematic genetic testing for personalised ovarian cancer therapy (SIGNPOsT)

Genetic testing in ovarian cancer patients is now being implemented across the NHS.  It’s hoped that by doing this, patients across the NHS will have even better treatments and that in some families, cancers will be prevented. This trial offers a genetic test to women with certain types of ovarian cancer. This is to detect gene alterations that may be a cause of ovarian cancer.

In this study we aim to find out more about:

  • what effect genetic counselling has on women’s emotional quality of life 
  • the gene changes women with ovarian cancer have
  • whether women with gene changes choose to have screening or treatment to prevent ovarian cancer
  • what are the costs of this new genetic testing strategy 

We also want to investigate the factors that affect the risk of developing ovarian cancer. This includes looking at how gene changes and other factors that might affect:

  • the risk of getting it
  • treatment 
  • how well the treatment works (outcome) 

SIGNPOST entails collecting samples including cancer, blood, and genetic information. 

The study is open to women who:

  • have had genetic testing 
  • have been offered testing but refused
  • haven’t had testing

For more information please visit:  https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-genetic-testing-for-ovarian-cancer-signpost

Evaluation of the BRCA-Direct SBRI programme

The team has conducted a service evaluation of the BRCA-DIRECT pathway to assess the impact of implementing unselected genetic testing at the point of breast cancer diagnosis in London.

This evaluation encompassed clinical service performance, cost-effectiveness modelling, and patient satisfaction.

We have preliminary data we have presented recently at the BGCS Annual Scientific Meeting, and are working towards disseminating these results soon. 

Evaluation of NHS Jewish BRCA Testing Programme
The Jewish BRCA Testing Programme is being implemented by the NHS National Cancer Programme team, working with ICR, North Thames GLH, Royal Marsden Hospital, Manchester and QMUL teams along with community organisations and stakeholders including Chai Cancer Care and Jnetics.

For more information please visit J-BRCA (nhsjewishbrcaprogramme.org.uk)

Genetic testing for Lynch syndrome at endometrial cancer diagnosis e-learning modules
This teaching programme aims to develop the skills, knowledge, and confidence of gynaecology and gynaecological cancer care professionals in delivering testing for Lynch syndrome for patients diagnosed with endometrial cancer. This is to support implementation of the national standard set by NICE diagnostic guidance 42 as well as other national and international guidelines on Lynch syndrome testing for all women with endometrial cancer. 

For more information please visit https://learninghub.nhs.uk/catalogue/ec-lynch-testing/about

Acceptability of risk-reducing strategies at different lifetime risk thresholds to reduce the risk of breast cancer

Now that we have identified the lifetime risk threshold of breast cancer at which a risk-reducing mastectomy (RRM) would be cost-effective, it is important prior to clinical implementation to evaluate the acceptability of this risk-reducing strategy. 

We will be undertaking a vignette study and randomising general population women into 5 groups with different lifetime risks of breast cancer, and asking a series of questions on acceptability of RRM. 

MISSION-O: Menopausal Impact of Opportunistic Salpingectomy for Ovarian Cancer Prevention

Previous studies have analyzed complications and menopausal symptoms of opportunistic salpingectomy (removing the fallopian tubes during other gynecological surgeries), but so far have not evaluated the age of menopause – an important factor because early menopause can have negative consequences for bone health, the cardiovascular system, sexual health and cognitive function.

We will analyze blood samples from participants in the HOPPSA study, where 2,700 women have undergone hysterectomy with or without opportunistic salpingectomy. They are offered to provide blood samples on two occasions: 1–8 and 2–9 years after the operation. In this way, we can compare the age of menopause between those who have undergone opportunistic salpingectomy and those who have not.

Cost-effectiveness of colorectal cancer screening for people in the UK with Lynch syndrome

This project will evaluate the cost-effectiveness of colorectal cancer surveillance for people in the UK with Lynch syndrome, in collaboration with teams at St Mark’s Hospital and Amsterdam University Medical Center (UMC).

Using retrospective, patient-level colonoscopy records and established colorectal cancer simulation models adapted for Lynch syndrome, we will estimate the costs and health outcomes of alternative surveillance schedules. Results may help quantify the potential benefits of identifying Lynch syndrome via genetic testing and inform future policy and guideline development for colorectal cancer prevention in this population.